PHASE 1b STUDY OF PTC596 IN COMBINATION WITH DACARBAZINE IN PATIENTS WITH LOCALLY RECURRENT, UNRESECTABLE OR METASTATIC RELAPSED/REFRACTORY LEIOMYOSARCOMA (LMS)
|PTC Therapeutics, Inc.
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / email@example.com
The purpose of this study is to evaluate the effectiveness of a new investigational drug, PTC596, used in combination with dacarbazine, for the treatment of locally recurrent, unresectable, or metastatic relapsed/refractory leiomyosarcoma, a type of soft tissue sarcoma. The purpose of this study is to evaluate whether adding PTC596 to dacarbazine is safe and whether the combination may work better than dacarbazine alone. Approximately 20 people will take part in this study at 1 site in the US.
This study is closed
Matthew Ingham, MD
|Are you 18 years of age or older?
|Have you been diagnosed with unresectable or metastatic leiomyosarcoma (LMS)?
|Do you have measurable disease?
|Are you able to swallow oral medication?
|Has it been at least 4 weeks since your last surgery?